FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128016811> ?p ?o ?g. }

• W3128016811 endingPage "2051" @default.
• W3128016811 startingPage "2051" @default.
• W3128016811 abstract "Background: Severe aplastic anemia (SAA) is a fatal disorder in children if treated inappropriately. According to the current algorithm, transplantation from a matched related donor (MRD) is recommended as the first-line option in children with SAA, if a MRD is unavailable, IST with a combination of anti-thymocyte globulin (ATG) and cyclosporine (CsA) represents the first-line choice. However, numerous limitations of immunosuppressive therapy (IST) exists. IST children may have incomplete recovery, and appear to be associated with an increased risk of clonal evolution and subsequent relapse. Additionally, the unavailability of horse-ATG in China also make the response of IST at a discount greatly. At the same time, great progresses in recent years in haploidentical transplantation might also promote changes in the algorithm of SAA treatment. Methods: We retrospectively compared the outcomes of children with SAA who received IST or who underwent hematopoietic stem cell transplantation (HSCT) from a haplo-identical donor (HID) as first-line choice between 2007 and 2016. The conditioning regimen for SCT from a haploidentical donor consisted of intravenous busulfan, cyclophosphamide and rabbit ATG. All of children were administered with granulocyte colonystimulating factor (G-CSF)-primed bone marrow (BM) combined with G-CSF-primed peripheral blood (PB) hematopoietic stem cells. Results: A total of 52 SAA children under the age of 17 years were initially treated with IST (n=24) or haplo-identical HSCT (n=28) as first-line choice. The last follow-up for all surviving patients was June 1, 2017. In IST group, by 6 months, 15 of the 21 subjects (71.4%) improved with first-line IST and achieved a partial response (n=10) or complete response (n=5). In SCT group, 27 patients (96.4%) achieved primary engraftment at a median of 12 (range, 10-21) days except one suffered from primary graft failure. The cumulative incidences (CI) of grade II-IV and of grade III-IV acute graft versus host disease (GVHD) were 48.1±1.0% and 11.1±0.4%, respectively. The 3-year CI of extensive chronic GVHD was 3.7±0.1%. The estimated 10-year overall survival were 73.4±12.6% and 89.3±5.8% in patients treated with IST or HID-HSCT (P=0.806). However, the failure-free survival was significantly inferior in patients receiving IST than in those undergoing transplantation from a HID [52.6±10.5% versus 89.3±5.8, P=0.008]. In univariate analysis, the choice of first-line immunosuppressive therapy was the only adverse predictor for failure-free survival. At the last follow-up, completely normal blood count was observed in 11 of 20 (55.0%) and 24 of 25 (96.0%) alive cases in IST and HID-HSCT cohort (P=0.003). Conclusions: Based on the superior FFS, high rate of engraftment and acceptable incidence of GVHD, the choice of HID HSCT for SAA children without a matched related donor as a first choice option seems reasonable. These suggest that SCT from a haplo-identical donor could be considered as first-line choice in children who lack a matched related donor, especially in experienced transplantation centers. Disclosures No relevant conflicts of interest to declare." @default.
• W3128016811 created "2021-02-15" @default.
• W3128016811 creator A5002188808 @default.
• W3128016811 creator A5011029344 @default.
• W3128016811 creator A5014867566 @default.
• W3128016811 creator A5038290266 @default.
• W3128016811 creator A5046424825 @default.
• W3128016811 creator A5051211027 @default.
• W3128016811 creator A5054247393 @default.
• W3128016811 creator A5061407928 @default.
• W3128016811 creator A5062474943 @default.
• W3128016811 creator A5065894155 @default.
• W3128016811 creator A5067347223 @default.
• W3128016811 creator A5079594267 @default.
• W3128016811 creator A5087371257 @default.
• W3128016811 creator A5087610827 @default.
• W3128016811 date "2017-12-07" @default.
• W3128016811 modified "2023-09-27" @default.
• W3128016811 title "First-Line Choice for Severe Aplastic Anemia in Children: Transplantation from a Haplo-Identical Donor Versus Immunosuppressive Therapy" @default.
• W3128016811 doi "https://doi.org/10.1182/blood.v130.suppl_1.2051.2051" @default.
• W3128016811 hasPublicationYear "2017" @default.
• W3128016811 type Work @default.
• W3128016811 sameAs 3128016811 @default.
• W3128016811 citedByCount "0" @default.
• W3128016811 crossrefType "journal-article" @default.
• W3128016811 hasAuthorship W3128016811A5002188808 @default.
• W3128016811 hasAuthorship W3128016811A5011029344 @default.
• W3128016811 hasAuthorship W3128016811A5014867566 @default.
• W3128016811 hasAuthorship W3128016811A5038290266 @default.
• W3128016811 hasAuthorship W3128016811A5046424825 @default.
• W3128016811 hasAuthorship W3128016811A5051211027 @default.
• W3128016811 hasAuthorship W3128016811A5054247393 @default.
• W3128016811 hasAuthorship W3128016811A5061407928 @default.
• W3128016811 hasAuthorship W3128016811A5062474943 @default.
• W3128016811 hasAuthorship W3128016811A5065894155 @default.
• W3128016811 hasAuthorship W3128016811A5067347223 @default.
• W3128016811 hasAuthorship W3128016811A5079594267 @default.
• W3128016811 hasAuthorship W3128016811A5087371257 @default.
• W3128016811 hasAuthorship W3128016811A5087610827 @default.
• W3128016811 hasConcept C126322002 @default.
• W3128016811 hasConcept C187212893 @default.
• W3128016811 hasConcept C203014093 @default.
• W3128016811 hasConcept C2776694085 @default.
• W3128016811 hasConcept C2776755627 @default.
• W3128016811 hasConcept C2777408962 @default.
• W3128016811 hasConcept C2779263901 @default.
• W3128016811 hasConcept C2780007613 @default.
• W3128016811 hasConcept C2780611847 @default.
• W3128016811 hasConcept C2781440808 @default.
• W3128016811 hasConcept C2911091166 @default.
• W3128016811 hasConcept C71924100 @default.
• W3128016811 hasConcept C90924648 @default.
• W3128016811 hasConceptScore W3128016811C126322002 @default.
• W3128016811 hasConceptScore W3128016811C187212893 @default.
• W3128016811 hasConceptScore W3128016811C203014093 @default.
• W3128016811 hasConceptScore W3128016811C2776694085 @default.
• W3128016811 hasConceptScore W3128016811C2776755627 @default.
• W3128016811 hasConceptScore W3128016811C2777408962 @default.
• W3128016811 hasConceptScore W3128016811C2779263901 @default.
• W3128016811 hasConceptScore W3128016811C2780007613 @default.
• W3128016811 hasConceptScore W3128016811C2780611847 @default.
• W3128016811 hasConceptScore W3128016811C2781440808 @default.
• W3128016811 hasConceptScore W3128016811C2911091166 @default.
• W3128016811 hasConceptScore W3128016811C71924100 @default.
• W3128016811 hasConceptScore W3128016811C90924648 @default.
• W3128016811 hasLocation W31280168111 @default.
• W3128016811 hasOpenAccess W3128016811 @default.
• W3128016811 hasPrimaryLocation W31280168111 @default.
• W3128016811 hasRelatedWork W1473782864 @default.
• W3128016811 hasRelatedWork W1968262670 @default.
• W3128016811 hasRelatedWork W2259317660 @default.
• W3128016811 hasRelatedWork W2551393047 @default.
• W3128016811 hasRelatedWork W2561753137 @default.
• W3128016811 hasRelatedWork W2563025182 @default.
• W3128016811 hasRelatedWork W2566503013 @default.
• W3128016811 hasRelatedWork W2573430916 @default.
• W3128016811 hasRelatedWork W2579680808 @default.
• W3128016811 hasRelatedWork W2620457262 @default.
• W3128016811 hasRelatedWork W2735009751 @default.
• W3128016811 hasRelatedWork W2777052989 @default.
• W3128016811 hasRelatedWork W2970680217 @default.
• W3128016811 hasRelatedWork W2979628503 @default.
• W3128016811 hasRelatedWork W2979815335 @default.
• W3128016811 hasRelatedWork W2991800170 @default.
• W3128016811 hasRelatedWork W3032062081 @default.
• W3128016811 hasRelatedWork W3032225454 @default.
• W3128016811 hasRelatedWork W3129641097 @default.
• W3128016811 hasRelatedWork W3165907277 @default.
• W3128016811 hasVolume "130" @default.
• W3128016811 isParatext "false" @default.
• W3128016811 isRetracted "false" @default.
• W3128016811 magId "3128016811" @default.
• W3128016811 workType "article" @default.